The Hematology ASH Education Program 2022 provides review articles from the Education Program at the 2022 ASH Annual Meeting. In this publication, each chapter relates to a different session presented at the meeting, spanning the spectrum from basic discovery and disease pathogenesis to the clinical application at the bedside.
This activity is supported by educational grants from AstraZeneca; GlaxoSmithKline; Incyte Corp.; Jazz Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; and Novartis Pharmaceuticals Corp.
Cover Image: Illustration of a blood clot with red blood cells (red), white blood cells (blue), and activated platelets (purple).
Source: Thom Leach/Science Photo Library
- Understand the data that support and challenge the use of ASCT in first remission in younger, fit MCL patients
- Understand that the presence of TP53 mutation is associated with a poor response to standard chemoimmunotherapy, including ASCT
- Review the use of novel therapies and MRD assessment in clinical trials that will help define the future role of ASCT in the modern era
- Identify key components to consider in the preoperative planning for patients with hemophilia
- Understand the goals of factor replacement during the perioperative period
- Review the available published literature on haploidentical vs cord blood transplantation
- Discuss the available literature that should guide decisions regarding haploidentical vs cord blood transplantation for an adult patient with a high-risk hematological malignancy in need of allogeneic transplantation